Personal information

No personal information available

Activities

Collapse all

Employment (1)

Pfizer Global Research and Development La Jolla: La Jolla, CA, US

2017-10 to present
Employment
Source: Self-asserted source
Mohamed Elmeliegy

Education and qualifications (1)

University of Tennessee Health Science Center: Memphis, TN, US

2012-05 | Dr.
Education
Source: Self-asserted source
Mohamed Elmeliegy

Works (13)

Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma

Targeted Oncology
2025-02-25 | Journal article
DOI: 10.1007/s11523-025-01134-8
Contributors: Mohamed Elmeliegy; Andrea Viqueira; Erik Vandendries; Anne Hickman; Umberto Conte; Donald Irby; Jennifer Hibma; Hoi-Kei Lon; Joseph Piscitelli; Pooneh Soltantabar et al.
Source: check_circle
Crossref

A Novel Two‐Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients

Clinical Pharmacology & Therapeutics
2025-02-16 | Journal article
DOI: 10.1002/cpt.3533
Contributors: Donald Irby; Jennifer Hibma; Mohamed Elmeliegy; Diane Wang; Erik Vandendries; Kamrine Poels; Blerta Shtylla; Jason H. Williams
Source: check_circle
Crossref

Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T‐Cell Engagers Development in Oncology

Clinical Pharmacology & Therapeutics
2024-09 | Journal article
DOI: 10.1002/cpt.3361
Contributors: Mohamed Elmeliegy; Joseph Chen; Aruna Dontabhaktuni; Allison Gaudy; Georgi I. Kapitanov; Junyi Li; Sabiha R. Mim; Sharad Sharma; Qin Sun; Sihem Ait‐Oudhia
Source: check_circle
Crossref

Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta‐Analysis

Clinical Pharmacology & Therapeutics
2024-06 | Journal article
DOI: 10.1002/cpt.3223
Contributors: Pooneh Soltantabar; Sheena Sharma; Diane Wang; Hoi‐Kei Lon; Akos Czibere; Anne Hickmann; Mohamed Elmeliegy
Source: check_circle
Crossref

Case–control matching‐guided exposure‐efficacy relationship for avelumab in patients with urothelial carcinoma

CPT: Pharmacometrics & Systems Pharmacology
2023-12 | Journal article
DOI: 10.1002/psp4.13049
Contributors: Pooneh Soltantabar; Ali Alhadab; Jennifer Hibma; Satrajit Roychoudhury; Diane D. Wang; Carlo Bello; Mohamed Elmeliegy
Source: check_circle
Crossref

Optimizing benefit/risk in oncology: Review of post-marketing dose optimization and reflections on the road ahead

Critical Reviews in Oncology/Hematology
2023-02 | Journal article
DOI: 10.1016/j.critrevonc.2023.103913
Contributors: Pooneh Soltantabar; Hoi-Kei Lon; Kourosh Parivar; Diane D. Wang; Mohamed Elmeliegy
Source: check_circle
Crossref

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design

Future Oncology
2022-02 | Journal article
DOI: 10.2217/fon-2021-0811
Contributors: Neeraj Agarwal; Arun Azad; Neal D Shore; Joan Carles; Andre P Fay; Curtis Dunshee; Lawrence Ivan Karsh; Maria Luisa Paccagnella; Nicola Di Santo; Mohamed Elmeliegy et al.
Source: check_circle
Crossref

Considerations on the Calculation of the Human Equivalent Dose from Toxicology Studies for Biologic Anticancer Agents

Clinical Pharmacokinetics
2021-05-02 | Journal article
DOI: 10.1007/s40262-021-00987-2
Contributors: Mohamed Elmeliegy; Chandrasekhar Udata; Ken Liao; Donghua Yin
Source: check_circle
Crossref

Discordance Between Child‐Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds

The Journal of Clinical Pharmacology
2021-01 | Journal article
DOI: 10.1002/jcph.1702
Contributors: Mohamed Elmeliegy; Derek Z. Yang; Engie Salama; Kourosh Parivar; Diane D. Wang
Source: check_circle
Crossref

Exposure‐Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials

The Journal of Clinical Pharmacology
2020-10 | Journal article
DOI: 10.1002/jcph.1626
Contributors: Mohamed Elmeliegy; Yanke Yu; Jennifer K. Litton; Akos Czibere; Gary G. Wilson; Iulia Cristina Tudor; Jenny Zheng; Diane D. Wang
Source: check_circle
Crossref

Talazoparib Exposure‐Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial

The Journal of Clinical Pharmacology
2020-10 | Journal article
DOI: 10.1002/jcph.1623
Contributors: Yanke Yu; Mohamed Elmeliegy; Jennifer K. Litton; Iulia Cristina Tudor; Akos Czibere; Jenny Zheng; Diane D. Wang
Source: check_circle
Crossref

Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia

Cancer Chemotherapy and Pharmacology
2020-09-03 | Journal article
DOI: 10.1007/s00280-020-04114-z
Contributors: Mohamed Elmeliegy; Jason Den Haese; Chetasi Talati; Meir Wetzler; William J. Jusko
Source: check_circle
Crossref

Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies

Clinical Pharmacokinetics
2020-06-13 | Journal article
DOI: 10.1007/s40262-020-00867-1
Contributors: Mohamed Elmeliegy; Manoli Vourvahis; Cen Guo; Diane D. Wang
Source: check_circle
Crossref
How many people are using ORCID?